STOCKS TELEGRAPH

Author: ST Staff

  • Sykes Enterprises, Incorporated (SYKE) stock is soaring today: Why is it so?

    Sykes Enterprises, Incorporated (SYKE) stock entered into the acquisition agreement with Sitel Group® today on June 18, 2021, after which the SYKE stock happened to be bullish, and the stock price soared by 30.51% to reach $53.73 a share as of this writing. The SYKE stock was bearish at the previous closing with a 0.02% drop. Let’s discuss more of it.

    What’s Happening?

    Sykes Enterprises, founded in 1977, is the digital transformation service provides along with customer management and multichannel demand generation services. SYKE signed a definitive merger agreement with Sitel Group®pursuant to which all of the outstanding shares of the SYKE’s common stock would be acquired by the Sitel via its subsidiary at a per-share purchase price of $54 which shows the premium of 31.2% on June 17, 2021, the closing price of SYKE stock and represents the total transaction of worth $2.2 billion. The all-cash transaction is expected to be complete in the second half of 2021.

    The Sitel Group® would recruit 155,000 employees in its offices across 39 countries representing over 600 clients with more than 50 languages. Furthermore,  This proposed transaction would help Sitel in increased growth along with strong customer relationships.

    First Quarter 2021 Financial Results:

    In the first week of the previous month on May 04, 2021, SYKE stock announced its first-quarter 2021 financial results according to which SYKE earnings per share increased by 17.39% as compared to the previous year to reach $0.81 per share, surpassed the estimate of 0.78$ per share. The first-quarter revenues increased by $46.7 million to reach $457.9 million as compared to $411.2 million in the same period of the prior year. Operating income showed a 29.3% increase over the year and the operating margin was 6.9% in the recently reported quarter.

    Second Quarter 2021 Financial Guidance:

    • SYKE stock anticipates its revenue for the second quarter of 2021 to be between $443 million to $448 million.
    • Non-GAAP basis effective tax rate would be 23% for the current quarter.
    • Diluted earnings per share is estimated to be in the range of $0.46 to 0.50 and the non-GAAP earnings per share is projected between $0.56 to $0.60.
    • Capital expenses for the SYKE stock in the second quarter would be between $15 million to $20 million.

    Conclusion:

    The acquisition agreement with Sitel Group® made the Skyes stock bullish today. According to first-quarter 2021 financial results and second-quarter guidance, the SYKE stock is showing significant growth over time. In a nutshell, SYKE can be a good bet for investors in the long run.

  • What Has Been Driving Meten EdtechX (METX) Stock Up In Premarket Session?

    What Has Been Driving Meten EdtechX (METX) Stock Up In Premarket Session?

    Shares of one of the leading omnichannel English language training (“ELT”) service providers in China, Meten EdtechX Education Group Ltd. (METX) have gained 6.19% in premarket trading at $1.03. At the end of the last trading session, METX added 0.52% to finish at $0.97. Meten EdtechX recorded a trading volume of 2.69 million shares, which is significantly below the average daily trading volume, which has been 9.34 million shares on average, for the last 50 days.

    Within the last five days, METX stock prices have declined -2.64%; however, they have lost -31.69% in the last month. In the last three months, the price of METX stock has fallen by -63.26% and has fallen by -51.50 percent so far this year. As a result of encouraging bill and enrollment numbers, METX stock has been rising.

    How have billing and enrollment at METX increased?

    Meten EdtechX is one of the leading companies in the English language teaching market, delivering training courses in English for Chinese students and professionals. METX provides its services under three industry-leading brands using an effective digital platform and a network of training centers across the country. Those brands include ABC (primarily junior ELT services) , Meten (adult and junior ELT services), and Likeshuo (online ELT).

    A unique combination of cutting-edge teaching technology and more than 25 years of experience make METX the perfect educational institution. A real-time learning analysis is a key component of METX’s AI-driven centralized teaching and management systems.

    Meten Meten EdtechX has announced an increase of 247.8% and 163.9% in gross billing and student enrollment in its junior ELT business in May 2021 compared to the same period last year.

    • There was also an increase of 92.4% and 65.2% in gross billing and student enrollment respectively compared to May 2019.
    • A year-over-year increase of 408.5% and a 120.4% increase over the same period in 2019 was recorded for METX’s junior ELT business in the first five months of 2021.
    • In May 2021, student renewals and referrals represented 57.7% of the total gross billing for METX’s junior ELT business, which indicates that the Company’s services have been well received by both students and their parents.
    • METX plans to continue its activities in junior quality-oriented education in response to recent policy changes.

    Other developments from METX:

    METX announced this week its plans to use non-fungible token (“NFT”) technology to verify the authenticity of courseware created by educators to prevent plagiarism, promote education reform, and motivate teachers. The Meten EdtechX (METX) team works towards realizing the dream of digitalizing, innovating, and decentralizing education industry as a whole through the use of blockchain technology and NFTs.

  • What Happened Last Session To Make Enzolytics (ENZC) Stock Drop?

    What Happened Last Session To Make Enzolytics (ENZC) Stock Drop?

    After dropping -2.38% in the last session, Enzolytics Inc (OTCPINK: ENZC) closed the last session at $0.2010, bringing its market cap to $562.39M. Enzolytics stock recently traded 42.22M shares, higher than the average daily volume of 41.93M. In addition, the shares have traded between $0.1821 and $0.2289. There are 2.80 billion outstanding shares compared to a float of 1.88 billion.

    As measured by performance, ENZC stock performed -27.44% last week and 57.40% last month. While the quarterly performance fell by 33.07 percent, the annual performance improved by 51.85 percent with a 215.05% six-month performance. ENZC stock prices ranged from $0.0002 – $0.9580 in the past 52 weeks. Despite announcing progress in clinical trials, ENZC stock dropped.

    What was the purpose of those clinical trials?

    Enzolytics is a pharmaceutical company dedicated to the development and commercialization of proprietary proteins and monoclonal antibodies to treat disease caused by debilitating infectious agents. A number of therapeutics are being developed by ENZC for the treatment of infectious diseases. Among the ENZC’s patented and clinically tested compounds, ITV-1 (Immune Therapeutic Vaccine-1) contains l-inactivated pepsin fraction (IPF) that has been shown effective in treating HIV/AIDS.

    A strategy by Enzolytics to advance its previously tested anti-HIV therapeutic ITV-1 to clinical trials and widespread distribution in Europe has been finalized.

    • ENZC will achieve a significant milestone for both human health and profitability when these steps are completed for its anti-HIV therapy.
    • An anti-HIV therapeutic developed by ENZC earlier made progress toward Bulgarian Drug Agency (BDA) certification, however that process was interrupted before it was completed.
    • A significant number of positive results from clinical trials were nevertheless documented during that period.
    • ENZC has no doubt that the clinical trials under the European Medicines Agency (EMA) will similarly succeed as a result of these positive results

    How ENZC will go through it?

    International Medical Partners Ltd. (IMPL) was formed by Enzolytics (ENZC) and European-based partners. IMPL is owned equally by ENZC and its partners and has the licenses to distribute the ITV-1 therapeutic in the 27 European countries covered by the European Medical Agency including Russia and its ex-Soviet states.

    For the initial production of ITV-1, ENZC engages Danhson Ltd., a Contract Manufacturing Company (CMO) for use in preparing the Best Methods Report for future production and clinical trial documentation.

  • Is This Why The Rolls-Royce (RLLCF) Stock Fell Last Trading?

    Is This Why The Rolls-Royce (RLLCF) Stock Fell Last Trading?

    On Thursday, Rolls-Royce Holdings Plc (OTCPk: RLLCF) closed down -21.94 percent at $0.0370, and has been trading between $0.0550 and $0.0311 on the day. During the last month, Rolls-Royce stock rose 145.57%; with 24.81M shares changing hands. In the last three months, RLLCF stock has gained over 35.04%, with average volume of 12.90M.

    Last 12 months have been good for the RLLCF stock with over 537.10% gain in stock price, reaching a high of $1.0055 with a $806.63B market cap. RLLCF stock price fell even after it announced plans for net zero emissions by 2050.

    What plans did RLLCF have?

    In addition to providing power to land, sea and air vessels, Rolls-Royce also produces aeronautical engines. With offices and service centers in 50 countries, RLLCF operates in a variety of sectors. RLLCF is involved in the following business segments through its subsidiaries and joint ventures: Civil Aerospace, Defense, Marine Systems, Energy, and Financial Services.

    Britain’s Rolls-Royce, which makes engines for planes and ships, outlined plans to reach net zero emissions by 2050 by increasing investments in decarbonizing technologies and using more sustainable aviation fuel in the short term.

    • In light of the current use of fossil fuels in RLLCF’s products and the increasing global demand for power, Rolls-Royce chief executive Warren East said that decarbonising was a particularly challenging task.
    • RLLCF also provided a commercial opportunity by planning to have all its new products compatible with net zero targets by 2030, in order to achieve net zero by 2050 at the latest.
    • In order to reach that target, RLLCF will spend 75% of its total budget on low carbon and net zero technologies by 2025, up from about 50% today.
    • Over 1 billion pounds are spent on R&D by RLLCF annually, though that number declined in 2020 as the pandemic put strain on the company.
    • RLLCF plans to make its largest business of aviation, compatible with 100% sustainable aviation fuels (SAF) by 2023, which generate a 70 percent lower carbon footprint than conventional fuel.
    • Additionally, RLLCF is pursuing less carbon-intensive options like hybrids, electric, and hydrogen in the longer term.

    RLLCF’s hydrogen plans:

    Paul Stein, vice president of technology, said that the Rolls-Royce (RLLCF) is in the process of discussing hydrogen with Airbus. Using small modular reactors, RLLCF can also develop an e-fuel by the mid-2030s, which can eventually replace sustainable aviation fuel.

  • Why The Moxian (MOXC) Stock Losing Grounds Premarket?

    Why The Moxian (MOXC) Stock Losing Grounds Premarket?

    In premarket trading, shares of offline-to-online (O2O) social media services and Internet media marketing services provider Moxian Inc. (MOXC) fell -12.64% to trade at $10.30. Thursday’s closing price of $11.79 was a gain of 0.60% for the MOXC stock. Moxian stock volume fell to 0.71 million shares, significantly less than the average daily volume of 1.75 million shares over the past 50 days.

    Because MOXC stock has been falling without any current news, we can therefore refer to recent developments to gain a deeper understanding of MOXC.

    How did things go at MOXC recently?

    Founded Moxian was founded in 2013 in Beijing, China, and has subsidiaries in Malaysia and Hong Kong. MOXC is a provider of social media and Internet marketing services, as well as an O2O integrated platform operator. Chinese social network MOXC integrates social media and business into a single platform.

    MOXC’s products and services provide merchant clients with the ability to study consumer behavior through interaction with users. MOXC provides services to small and medium-sized businesses. The company had been called Moxian China, Inc. until July 2015, when its name changed to Moxian, Inc.

    In Recent developments have resulted in Moxian terminating its proposed merger with the Btab Group, Inc., a Delaware corporation.

    • The agreement was terminated by mutual consent in accordance with the terms of the August 27, 2020 Share Exchange Agreement.
    • MOXC and Btab Group signed a material share exchange agreement in August last year.
    • A portion of the MOXC common stock , 59 million, and a portion of the MOXC class A preferred stock , 50 million would have to be issued pursuant to the agreement.
    • In a business combination that will produce a merged entity with a value of over $400 million and an annual revenue of at least $40 million, those MOXC shares were to be issued in exchange for the entire equity of Btab.

    Insight into MOXC performance:

    Alternatively, if no relevant news are available, the stock’s performance could provide a better insight into its potential. MOXC shares have risen by 1055.88% over the last 12 months, but they have declined by -24.37% over the past week. MOXC stock has gained 251.94% over the past three months, while it has gained 821.09% over the past six months. Aside from that, the share count stands at 16.19 million shares and the market capitalization of the company is $240.16 million.

  • Almaden Minerals Ltd. (AAU) Stock Continues Downward Trend Following Culmination of Ixtaca IP Program

    Almaden Minerals Ltd. (AAU) Stock Continues Downward Trend Following Culmination of Ixtaca IP Program

    Almaden Minerals Ltd. (AAU) stock prices were down a marginal 2.03% as of the market closing on June 17th, 2021, bringing the price per share down to USD$0.5058 at the end of the trading day. Subsequent premarket trading has seen the stock remain stable as of the time of writing.

    Completion of Ixtaca IP Program

    The company announced on June 14th, 2021 that it had successfully completed a surface-induced polarization geophysical (IP) program at its Ixtaca deposit in Mexico. The work being conducted was designed to help isolate drill targets under the area of hydrothermal alteration called the Southeast Alteration zone, as well as at depth beneath the Ixtaca deposit.

    Results of IP Program

    The data collected will continue to be processed and combined with historic geologic, geochemical, and geophysical data. AAU hopes that these results will facilitate the identification of additional discrete targets for a future diamond drill program. This program will serve to test for potential blind zones of veining under the Southeast Alteration zone, which is mostly covered with overlying clay alteration similar to that in the SE alteration zone. The discovery drill hole in the original Ixtaca deposit area was planned partly due to high resistivity and chargeability results obtained in an earlier IP geophysical survey.

    SE Alteration Zone

    The SE Alteration zone is made up of white argillic volcanics and clusters of anomalies that were identified from a hyperspectral survey. This survey included spectral signatures of important epithermal alteration minerals such as kaolinite, alunite, and buddingtonite. November 2020 saw the company announce the discovery of a network of veining cropping out within the SE Alteration zone. Seventeen samples of the veining were collected and submitted to ALS Global in Mexico for analysis.

    Analysis of Samples

    Sixteen of the samples returned below detection gold and silver, with the odd one out returning a value of 62 ppb gold. Despite the outcrops being leached and weathered, however, many of the samples exhibited higher values for epithermal pathfinder elements, which are commonly found in the higher parts of epithermal alteration zones. These findings are highly promising in their support of the company’s claim that the SE Alteration zone has the potential to represent higher levels of a potential underlying epithermal system.

    Future Outlook for AAU

    Equipped with the recent development of the potential of its digsites, AAU is poised to capitalize on the opportunities presented to it to return to its trajectory of growth. Current and potential investors are hopeful that management will leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.

  • Why CNS Pharmaceuticals, Inc. (CNSP) stock is Climbing in Pre-Market today?

    Why CNS Pharmaceuticals, Inc. (CNSP) stock is Climbing in Pre-Market today?

    Shares of the CNS Pharmaceuticals, Inc. (CNSP) stock were climbing in the Pre-market today on June 18, 2021, following the announcement made by CNS pharmaceuticals yesterday that it has been selected to be included in Russell 2000® Index. The CNSP stock price saw a push of 4.00% to reach $2.08 a share at the time of this writing. CNSP stock climbed 3.09% at the previous closing. Let’s take a closer look at current happenings.

    What’s Happening?

    CNS Pharmaceuticals, Inc, founded in 2017, develops the anticancer drugs that are used to treat brain and central nervous system tumors. CNSP addition in Russell 2000® Index would be effective from after closing of U.S. equity markets on June 25, 2021. This inclusion would help the CNSP stock to drive market awareness for its clinical program in the fight against glioblastoma multiforme (GBM) disease.

    The Russell 2000® Index is the subset of the Russell 3000® Index in which  2,000 smallest securities based on current index membership and market cap combination are added. It evaluates the performance of these smallest securities and constitutes  10% of the total market capitalization of its parent index.

    Patient Enrollment:

    Back to the previous month on May 19, 2021, CNSP stock did announce the commencing of patient enrollment in its potential pivotal study that was intended to evaluate the efficacy as well as safety of Berubicin when it is used to treat adult recurrent Glioblastoma Multiforme (GBM). The CNS pharmaceuticals planned 210 patients in its 35 clinical sites in the United States and also expressed the wish to extend the trial in Western Europe. The primary endpoint for the study was overall survival.

    Financial View of CNSP stock:

    On May 14, 2021, CNSP stock released its first-quarter 2021 financial results according to which a $3.6 million net loss was reported higher than $2.0 million in the same quarter of the previous year. Research and development expenses increased by $1.6 million in the recently reported quarter to reach $2.2 million as compared to the same prior-year period. The quarter ended with $11.0 million cash and cash equivalents which according to CNSP stock’s management is enough to fund operation during the current year.

    Conclusion:

    The CNSP stock is continuing the rising momentum after the announcement of its selection in the Russell 2000® Index. The stock is growing with time and has enough cash to fund its operations for next year. Hence investors need to keep this stock on their books.

  • Osmotica Pharma PLC (OSMT) Stock Recovering Following Continued Growth of Upneeq

    Osmotica Pharma PLC (OSMT) Stock Recovering Following Continued Growth of Upneeq

    Osmotica Pharma PLC (OSMT) stock prices stayed stable over the course of the market day on June 17th, 2021. Subsequent pre-market fluctuations have seen the stock climb by 3.74%, bringing it up to USD$3.05.

    Upneeq Snowball Effect

    The first quarter of the fiscal year 2021 saw the company ride the momentum generated by the earlier launch of Upneeq, the first and only FDA-approved ophthalmic solution for the treatment of acquired ptosis in adults. The growth accelerated since the launch, with Q1 2021 having reported a 74% quarter-over-quarter growth in paid subscriptions. Paid subscriptions for the month of April were 17% higher than the previous month, reflecting the increased exposure of Upneeq and the familiarity of more and more eye care professionals with it. The company is keen to spearhead its market penetration and expand the scope of exposure of Upneeq.

    Upneeq Developments

    Upneeq established itself as an invaluable asset with it being awarded the 2021 Medtech Breakthrough Award. The company’s partner, Santen Pharma, had a successful meeting with the Japanese equivalent of the FDA, the PMDA, and subsequently made plans to initiate clinical trials in the very near future. The success of the meeting was reflected by the USD$10 million milestone as per its licensing agreement, which it anticipates receiving in the second quarter of 2021.

    Arbaclofen

    The company has submitted a revised study protocol of arbaclofen to the FDA, with the belief that the treatment has the potential to play an essential role in MS spasticity. OMST is also in advanced discussions with several parties as a part of the previously announced execution of its strategic process focus on its legacy portfolio.

    Financial Reports

    Revenues for the first quarter of the fiscal year 2021 came in at USD$23.9 million, down from the USD$48.6 million reported in the prior year quarter. Net loss was on the rise, with Q1 2021 reporting USD$9.6 million, up from the USD$3.1 million net loss reported for the first quarter of 2020. As of March 31st, 2021, the company reported cash and cash equivalents on the amount of USD$109.2 million, against a debt of USD$219.8 million.

    Future Outlook for OSMT

    Armed with the continuously expanding actualization of the commercial potential of Upneeq, OSMT is poised to return to its trajectory of growth after a consistent few days of the stock trending down. Current and potential investors are hopeful that management will leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.

  • What Caused HCMC Stock To Fall Nearly 8%?

    What Caused HCMC Stock To Fall Nearly 8%?

    Healthier Choices Management Corp. (OTCPink: HCMC) ended Thursday’s trading session down -7.69 percent at $0.0012 and has been trading in a day range of $0.0013 to $0.0011. HCMC stock has dropped more than -25.00% in the last month, with over 1.88B shares exchanged.

    In terms of three-month performance, HCMC stock lost over 14.29% while volume averaged 2.05B. HCMC stock gained over 1100.00% during the past 12 months, reaching a high of $0.0065 with a market cap of $370.71M. HCMC stock plummeted following news of a petition for a review by the Patent Trial and Appeal Board (PTAB).

    For what purpose was that filing made?

    Healthier Choices aims to provide consumers with better nutritional options and health-oriented lifestyle choices. HCMC manages a portfolio of intellectual property through its wholly owned subsidiary, HCMC Intellectual Property Holdings, LLC. A total of eight HCMC stores sell e-liquids, vaporizers, and other vape-related products in the Southeast region of the United States.

    Healthier Healthier Choices on Wednesday announced that Philip Morris Products SA (“Philip Morris”) had filed a petition with the Patent and Trademark Office’s PTAB.

    • Philip Morris sought to invalidate HCMC’s US Patent No. 10,561,170 through an inter parts review (“IPR”).
    • HCMC will be given three months to submit an optional preliminary response if Philip Morris’ IPR petition is accepted by the PTAB.
    • The PTAB will decide whether to begin the IPR proceedings within three to six months of Philip Morris’ IPR petition being accepted or after the HCMC responses are submitted.
    • The PTAB will issue a written decision as to the validity of either some or all claims in a Patent within one year of instituted IPR proceedings.
    • Philip Morris USA, Inc. and Philip Morris Products SA were previously sued by HCMC for patent infringement in connection with their product known and marketed as IQOS.
    • In its lawsuit, HCMC alleged that IQOS infringed on a patent.
    • HCMC filed the lawsuit in the United States District Court for the Northern District of Georgia.

    What HCMC is planning?

    In light of Philip Morris’s IPR petitions, HCMC intends to oppose the initiation of the IPR process vigorously. HCMC is now fully prepared for a vigorous defense of the validity of the Patent if the IPR process is instituted.

  • Did Anything Support OZSC Stock Last Trading?

    Did Anything Support OZSC Stock Last Trading?

    The stock of Ozop Energy Solutions Inc (OTCPINK: OZSC) closed down -0.81% on Thursday at $0.0793. During the session, Ozop stock’s price ranged from $0.0780 to $0.0810, while 30.04M of its shares were traded. OZSC stock remained almost stable thanks to positive development news.

    How did that development come about?

    Ozop is an innovator, designer, developer, manufacturer, and distributor of ultra-high-power chargers, inverters, and power supplies for many sectors including defense, heavy industry, aviation ground support, maritime, and more. By providing the assets and infrastructure necessary to store energy, OZSC plans to capture a significant share of the rapidly growing market for renewable energy.

    This week, Ozop announced its wholly-owned subsidiary Ozop Energy Systems, Inc. had entered into an agreement with Clean Peak Energy Group, LLC.

    • Using a building’s existing thermal mass and air conditioning systems, CPE is focused on storing energy and reducing carbon dioxide emissions associated with buildings.
    • Profit-sharing is included in the agreement for projects adopted by OZSC that use CPE solutions.
    • With CPE, which also offers competitive rates for commercial clients, OZSC will be able to offer their customers competitive electric supplies in states where such competition is available.
    • Facilities can reduce energy costs by using CPE’s advanced energy storage technology, and there is no capital investment required.
    • In addition to other services that OZSC can provide through its subsidiaries and alliances, this program will be of great interest to its customers.

    The agreement will benefit OZSC in what ways?

    CPE’s advanced technology and customer electricity supply programs will be available to OZSC’s customers and companies as a result of this agreement. The project will further strengthen the Neo-Grid system of clean technology products and services offered by Ozop (OZSC) to aid building owners and operators in reducing operating costs with safe, efficient, and energy-efficient facilities to help address the nation’s energy needs.